sector medic suppli devic
 mix fx drive upsid remain
cautiou competit launch
messag sale top consensu ep come
ahead beat driven larg fx howev growth slow
vs posit side manag struck bullish tone
outlook maintain guidanc despit reduc fx tailwind factor think
like carri weight friday stock reaction whether stock sustain
momentum ahead upcom competit len launch anoth stori
concern unlik abat near term view maintain neutral rate
mix quarter fx drive upsid revenu pro forma top
consensu adjust ep yoy come
street bulk upsid driven fx howev currenc boost
ep forecast offset
headwind combin higher interest expens tax make
beat less impress fx also ad extra sale manag maintain
guidanc despit dollar recent strength shave
compani full year fx tailwind exclud currenc paragard accret outlook
impli underli ep growth year
coopervis sale organ came consensu
currenc ad vs estim account beat
categori perspect upsid driven primarili out-performance single-
use sphere cc toric cc came
street respect elsewher multifoc cc ad
beat partial off-set shortfal non single-us sphere
flat cc geograph standpoint acceler growth america
off-set weaker perform emea cc busi slow
sequenti expect america growth continu improv balanc
year comp eas grey market activ cite headwind
past abat meanwhil asia pacif post ninth quarter double-digit growth
past ten sale rise pro forma estim silicon hydrogel len
sale rose forecast continu strength daili
sih franchis cc partial off-set on-going avaira weak franchis
transit new avaira vital brand overal extend wear sih sale rose
cc biofin continu post solid gain vital transit expect wrap
hope segment reacceler back half year
manag narrow revenu guidanc pro
forma pro forma growth expect come
improv perform view quarter modest step backward
estim global contact len sale rose cc calendar
acceler gain seen market healthi
time howev margin out-performance continu narrow manag
believ compress larg due competitor increas success drive
trade-up within instal base dynam result improv dollar share
without actual gain patient level may part stori sens
competit environ also tougher time
remain expect product launch alcon bausch
next quarter despit potenti near-term headwind manag
notabl bullish thursday call outlook balanc year
view optim encourag expect investor concern increas
competit go away yet
continu page
page analyst certif import disclosur
report basi len market share yoy calendar
alcon bausch also cede ground
beneficiari rel fourth quarter actual alcon demonstr
momentum larg js expens lost
sequenti expect global contact len market continu grow high end
histor rang go forward driven on-going penetr higher price
silicon hydrogel lens modal mix shift toward daili intersect
two trend daili sih categori account world-wide len sale
elsewher coopersurg top reduc expect revenu
pro forma come ahead consensu miss
office/surg product pro forma off-set fertil side
busi cc top reduc street expect
though qualiti beat somewhat light currenc ad extra
math dont believ street model factor april
acquisit lifeglob contribut quarter deal like add
anoth sale back half year howev boost expect
larg off-set decis exit carrier screen nipt busi
face signific price pressur focu core genom offer
meanwhil paragard contribut sale line expect
full year manag expect paragard revenu come slightli
prior guidanc model assum financi impact
paragard readili appar csi gross margin jump yoy
paragard fold profit improv base busi
manag confid csi see gm improv least low-
result thu far larg expect see paragard potenti
sourc top line upsid time especi follow last year new england
journal medicin studi link hormon contracept higher risk breast cancer
view manag decis begin build dedic sale forc market
paragard sign see enhanc upsid case product well
near-term howev tough paragard comp on-going fertil headwind could
limit upsid full year csi guidanc unchang pro forma
top line strong gross margin drove improv profit cooper fiscal
gross margin yoy came consensu
sg spend rose yoy sale came street
expect meanwhil spend grew yoy sale higher
consensu collect result fiscal ebita margin
yoy street estim final higher expect interest
expens tax rate combin reduc earn
adjust estim maintain neutral model call ep
total revenu pro forma compar
prior forecast respect project full year sale
pro forma csi expect contribut pro forma
long-term continu see top bottom line grower
modestli large-cap med-tech averag share look
somewhat attract basi trade revis ntm ep estim vs
group stock appear expens ebitda vs
continu view fairli valu current level
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal add scale coopersurg grow women health
presenc often overlook investor expect csi account
overal revenu growth fuel
primarili compani invest half dozen deal
build lead posit ivf genet test market follow recent
acquisit paragard intrauterin devic believ long-term
fundament market appeal see grow scale csi neg
broader invest case complic stori believ
investor would prefer look sole contact len play
share current trade ntm ep ntm ebitda
repres discount large-cap med-tech group averag price-to-earnings basi
slight premium ev/ebitda view attract level rel
compani long-term growth rate estim top
bottom line respect see potenti catalyst horizon drive
improv momentum stock competitor pois launch sever
import new product come month expect concern contact len
competit landscap continu weigh sentiment near-term result
maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur tax reform rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
